Skip to main content

Ibrance Side Effects

Generic name: palbociclib

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 4, 2023.

Note: This document contains side effect information about palbociclib. Some dosage forms listed on this page may not apply to the brand name Ibrance.

Applies to palbociclib: capsule oral, oral capsule, oral tablet.

Serious side effects of Ibrance

Along with its needed effects, palbociclib (the active ingredient contained in Ibrance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking palbociclib:

More common

Incidence not known

Other side effects of Ibrance

Some side effects of palbociclib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to palbociclib: oral capsule, oral tablet.

Hematologic

Very common (10% or more): Decreased white blood cells (95%), decreased neutrophils (94%), decreased hemoglobin (83%), decreased lymphocytes (81%), neutropenia (80%), decreased platelets (61%), leukopenia (39%), anemia (24%), thrombocytopenia (16%)

Frequency not reported: Febrile neutropenia[Ref]

Respiratory

Very common (10% or more): Upper respiratory infection (up to 31%), epistaxis (up to 11%)

Common (1% to 10%): Pulmonary embolism, interstitial lung disease, pneumonitis[Ref]

Other

Very common (10% or more): Fatigue (37%), asthenia (17%), pyrexia (12%)[Ref]

General

Most common adverse reactions (10% or greater incidence): Neutropenia, leukopenia, fatigue, anemia, infections, nausea, stomatitis, alopecia, diarrhea, thrombocytopenia, decreased appetite, vomiting, asthenia, peripheral neuropathy, and epistaxis.[Ref]

Gastrointestinal

Very common (10% or more): Nausea (35%), stomatitis (30%), diarrhea (26%), vomiting (16%)[Ref]

Dermatologic

Very common (10% or more): Alopecia (33%), rash (18%), dry skin (12%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (16%)[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (13%), dysgeusia (10%)[Ref]

Immunologic

Very common (10% or more): Infections (e.g., nasopharyngitis, upper respiratory tract infection, urinary tract infection, oral herpes, sinusitis, rhinitis, bronchitis, influenza, pneumonia, gastroenteritis, conjunctivitis, herpes zoster, pharyngitis, cellulitis, cystitis, lower respiratory tract infection, tooth infection, gingivitis, skin infection, gastroenteritis viral, respiratory tract infection, respiratory tract infection viral, folliculitis) (60%)[Ref]

Frequently asked questions

References

1. Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.